Email this article PROBLEMS OF FINAL PHASE POLIOMYELITIS ERADICATION PROGRAMME
- Authors: Chernyavskaya O.P.1, Briko N.I.1
-
Affiliations:
- Sechenov First Moscow State Medical University
- Issue: Vol 94, No 4 (2017)
- Pages: 75-81
- Section: TOPICAL ISSUES IN SCIENCE
- Submitted: 10.04.2019
- Published: 28.08.2017
- URL: https://microbiol.crie.ru/jour/article/view/182
- DOI: https://doi.org/10.36233/0372-9311-2017-4-75-81
- ID: 182
Cite item
Full Text
Abstract
Never before has the world community were not so close to the goal - poliomyelitis eradication. In 2016, the world recorded only 37 cases in the three endemic countries: Pakistan, Afghanistan and Nigeria. Despite the great progress in the final stages of poliomyelitis eradication have problems: the emergence and circulation of vaccine-derived poliovirus and related diseases, vaccine-associated paralytic poliomyelitis, social and political factors affecting of vaccination.
About the authors
O. P. Chernyavskaya
Sechenov First Moscow State Medical University
Author for correspondence.
Email: noemail@neicon.ru
Россия
N. I. Briko
Sechenov First Moscow State Medical University
Email: noemail@neicon.ru
Россия
References
- Доклад секретариата «Полиомиелит». Исполнительный комитет ВОЗ 140 сессия п.7.3. http://apps.who.int/gb/ebwha/pdf_files/EB140/B140_13-ru.pdf.
- Иванова О.Е., Еремеева Т.П., Морозова Н.С. и др. Вакциноассоциированный паралитический полиомиелит в Российской Федерации в период изменения схемы вакцинации (2006-2013 гг.). Вопросы вирусологии. 2016, 61 (1): 9-15.
- Иванова О.Е., Сейбиль В.Б., Липская ЕЮ. и др. Вирусологическое и серологическое исследование вспышек полиомиелита в Чеченской Республике в 1995 г. Журн. микро-биол. 1996, 3: 11-13.
- Онищенко Г. Г., Ежлова Е.Б., Мельникова А.А. и др. Полиомиелит в Таджикистане. Защита территории России от заноса и распространения дикого вируса полиомиелита. Журн. микробиол. 2011, 2: 12-22.
- Онищенко, Г.Г., Дроздов С.Г. и др. Проблемы ликвидации полиомиелита. Санкт-Петербург, 2008.
- Стратегический план ликвидации полиомиелита и осуществления завершающего этапа в 2013-2018 гг. http://polioeradication.org.
- Alexander L.N., Seward J.F., Santibanez Т.А. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004, 292: 1696-1701.
- Centers for Disease Control and Prevention. Prolonged poliovirus excretion in an immunode-ficient person with vaccine-associated paralytic poliomyelitis. MMWR. 1997, 46: 641-643.
- Garon J., Patel M. The polio endgame: rationale behind the change in immunization. ADC Online First, published on January 17, 2017 as 10.1136/archdischi!d-2016-311171. http://adc. bmj.com/Downloaded from on January 18, 2017.
- Glynis Dunn, Dimitra Klapsa, Thomas Wilton et al. Twenty-Eight years of poliovirus replication in an immunodeflcient individual: Impact on the global polio eradication Initiative, Published: August 27, 2015, http://dx.doi.org/10.1371/journal.ppat. 1005114/.
- Henderson D.A., Witte J.J. Morris L.A., Langmuir D. Paralytic disease associated with oral polio vaccines, J. American Medical Association. 1964. 190:41-48.
- Kew O.M., Morris Glasgow V, Landaverde M. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002, 296: 356-359.
- Kew O.M., Sutter R.W., Nottay B. et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeflcient patient. J. Clinical Microbiology 1998, 36: 2893-2899.
- Minor P Characteristics of poliovirus strains from longterm excretors with primary immunodeficiencies. Developments in Biologicals. 2001, 105: 75-80.
- Nkowane B.M., Wassilak S.G.F., Orenstein W.A. Vaccine-associated paralytic poliomyelitis. United States 1973 through 1984. J. Amer. Med. Assoc. 1987, 257: 1335-1340.
- Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep, 1997, 46 (RR-3): 1-25.
Supplementary files
